ClinicalTrials.gg
RecruitingNCT07577505Updated Aug 20, 2026

Histidine Supplementation for Antitumor Immunity in Colorectal Cancer

An interventional study of Histidine in Colorectal Cancer, sponsored by Jing-yuan Fang, MD, Ph. D. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Jing-yuan Fang, MD, Ph. D · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
785th of 894
20 · median 80
Started
2026
with 117 others
No phase
150 of 1,139
81 open now
Primary completion
2026-12
later than 301 of 605 live
Registered
1,048th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 785th largest by planned enrollment of the 894 interventional ones that give a count, is one of 118 that started in 2026, is one of 150 with no phase, reaches primary completion later than 301 of the 605 other live ones, and was the 1,048th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.

Participants with colorectal cancer in the supplementation group will:

Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Histidine
  • Immune functions
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18-80 years, regardless of sex.
  2. (BMI) ≥18.5.
  3. NRS-2002 score \<3.
  4. Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.
  5. Capable of oral intake of medication.
  6. Willing to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment.
  2. Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding.
  3. Allergy to sample components.
  4. Current use of other nutritional supplements that may affect the validity and effectiveness of the study results.
  5. Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test.
  6. Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures.
  7. Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Histidine supplement group

    Patients with colorectal cancer will receive oral histidine supplementation in addition to standard anti-tumor treatment for 9 weeks.

    Dietary Supplement: Histidine

Interventions

  • Dietary supplementHistidine

    Histidine capsules, 1000 mg per capsule, taken orally as 2 capsules once daily for 9 weeks. Histidine supplementation will be administered in addition to standard anti-tumor treatment determined by the treating physician according to clinical guidelines.

06

What researchers measure

Primary outcomes

  1. Serum histidine concentration

    Serum histidine concentration measured using liquid chromatography-mass spectrometry (LC-MS).

    Time frame: At the time of enrollment as baseline, and at the end of treatment at 9 weeks.

  2. Percentage of IFN-gamma-positive T cells

    Peripheral blood mononuclear cells (PBMCs) collected from patients with colorectal cancer will be assessed by flow cytometry to evaluate the percentage of IFN-gamma-positive T cells as a T cell effector function marker.

    Time frame: At the time of enrollment as baseline, and at the end of treatment at 9 weeks.

  3. Percentage of granzyme B-positive T cells

    Peripheral blood mononuclear cells (PBMCs) collected from patients with colorectal cancer will be assessed by flow cytometry to evaluate the percentage of granzyme B-positive T cells as a T cell effector function marker.

    Time frame: At the time of enrollment as baseline, and at the end of treatment at 9 weeks.

Secondary outcomes

  1. Tumor volume

    Tumor volume will be assessed using available imaging examinations and/or colonoscopy findings, according to routine clinical evaluation in patients with colorectal cancer.

    Time frame: At the time of enrollment as baseline, and at the end of treatment at 9 weeks, and during follow-up at 3 and 6 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 7 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 11, 2026
StartActual
May 6, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07577505
Lead sponsor
Jing-yuan Fang, MD, Ph. D
Collaborators
Shanghai Punan Hospital of Pudong New District
Responsible party
Jing-yuan Fang, MD, Ph. D (Professor Dr. Jing-yuan Fang, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
May 11, 2026
Start date
May 6, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Wan Du, M.D.
Contact
duwan2017@126.com
(86)13788972966
Youli Chen
Contact
chenylpetri@gmail.com
(86)13656503169
Jing-Yuan Fang, M.D.
study director · Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Histidine

Start the discussion